常染色体显性多囊肾病患者腹膜透析结局:基于法国两项登记的国家回顾性研究
本研究基于法国REIN和RDPLF两项登记,回顾性分析2000至2010年开始透析的ADPKD患者。REIN登记中ADPKD腹膜透析患者638例,HD患者4653例;结果显示腹膜透析未对ADPKD患者总体生存产生负面影响,技术失败风险亦未因ADPKD状态而增加,腹膜透析是ADPKD患者的合理选择。
要点
- ADPKD患者腹膜透析与非ADPKD腹膜透析相比生存更好,且不增加技术失败或腹膜炎风险。
- ADPKD患者腹膜透析使用与肾移植发生正相关,与死亡无显著关联。
- 腹膜透析可用于经过选择的ADPKD患者,不应对其总体生存产生负面影响。
核心结论
- 腹膜透析未对ADPKD患者总体生存产生负面影响,且腹膜透析技术失败不受ADPKD状态影响,腹膜透析是ADPKD患者的合理选择。
研究设计与样本
- 基于法国REIN和RDPLF两项登记的两项回顾性研究,纳入2000至2010年开始透析的患者。
- REIN登记比较ADPKD腹膜透析患者(n=638)与ADPKD血液透析患者(n=4653)。
主要发现
- REIN登记中ADPKD患者采用腹膜透析者占ADPKD人群的10.91%,非ADPKD人群腹膜透析使用率为11.2%。
- 与ADPKD血液透析患者相比,ADPKD腹膜透析患者血清白蛋白更高(38.8 ± 5.3 versus 36.8 ± 5.7 g/dL,P < 0.0001),糖尿病比例更低(5.31 versus 7.71%,P < 0.03)。
- ADPKD患者使用腹膜透析与肾移植发生正相关,与死亡无显著关联(风险比1.15,95%置信区间0.84-1.58)。
- RDPLF登记中,与非ADPKD腹膜透析患者相比,ADPKD腹膜透析患者更年轻、合并症更少且生存更好。
- ADPKD状态与腹膜透析技术失败风险增加或腹膜炎风险增加无关。
临床怎么用
- 对于经过选择的ADPKD患者,腹膜透析可作为合理的肾脏替代治疗方式。
- 临床不应因ADPKD诊断而回避腹膜透析,需关注患者选择与合并症管理。
局限性
- 本研究为回顾性研究,存在选择偏倚可能。
- 研究基于法国登记数据,结论外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pathological features of autosomal dominant polycystic kidney disease (ADPKD) include enlarged kidney volume, higher frequency of digestive diverticulitis and abdominal wall hernias. Therefore, many nephrologists have concerns about the use of peritoneal dialysis (PD) in ADPKD patients. We aimed to analyse survival and technique failure in ADPKD patients treated with PD. METHODS: We conducted two retrospective studies on patients starting dialysis between 2000 and 2010. We used two French registries: the French Renal Epidemiology and Information Network (REIN) and the French language Peritoneal Dialysis Registry (RDPLF). Using the REIN registry, we compared the clinical features and outcomes of ADPKD patients on PD (n = 638) with those of ADPKD patients on haemodialysis (HD) (n = 4653); with the RDPLF registry, those same parameters were determined for ADPKD patients on PD (n = 797) and compared with those of non-ADPKD patients on PD (n = 12 059). RESULTS: A total of 5291 ADPKD patients and 12 059 non-ADPKD patients were included. Analysis of the REIN registry found that ADPKD patients treated with PD represented 10.91% of the ADPKD population. During the study period, PD was used for 11.2% of the non-ADPKD population. Compared with ADPKD patients on HD, ADPKD patients on PD had higher serum albumin levels (38.8 ± 5.3 versus 36.8 ± 5.7 g/dL, P < 0.0001) and were less frequently diabetic (5.31 versus 7.71%, P < 0.03). The use of PD in ADPKD patients was positively associated with the occurrence of a kidney transplantation but not with death [hazard ratio 1.15 (95% confidence interval 0.84-1.58)]. Analysis of the RDPLF registry found that compared with non-ADPKD patients on PD, ADPKD patients on PD were younger and had fewer comorbidities and better survival. ADPKD status was not associated with an increased risk of technique failure or an increased risk of peritonitis. CONCLUSIONS: According to our results, PD is proposed to a selected population of ADPKD patients, PD does not have a negative impact on ADPKD patients' overall survival and PD technique failure is not influenced by ADPKD status. Therefore PD is a reasonable option for ADPKD patients.
引用
- Sigogne M, Kanagaratnam L, Dupont V, et al. Outcome of autosomal dominant polycystic kidney disease patients on peritoneal dialysis: a national retrospective study based on two French registries (the French Language Peritoneal Dialysis Registry and the French Renal Epidemiology and Information Network). Nephrol Dial Transplant. 2018. PMID: 29361078. doi:10.1093/ndt/gfx364
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。